IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 151-175 out of 1291.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

Public Release: 30-Mar-2015
Nature Medicine
Researchers develop new potential drug for rare leukemia
Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.
National Institutes of Health, Leukemia and Lymphoma Society; American Cancer Society, Prostate Cancer Foundation, Howard Hughes Medical Institute, US Department of Defense

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 30-Mar-2015
Journal of Clinical Investigation
DNA alterations may predict treatment response in chronic myelomonocytic leukemia patients
A new study in the Journal of Clinical Investigation identifies a molecular signature that is predictive of chronic myelomonocytic leukemia patient response to the DNA methyltransferase inhibitor decitabine.
Leukemia and Lymphoma Society, Sass Foundation, National Institutes of Health, US Department of Defense, Josie Robertson Investigator Program, Damon Runyon Clinical Investigator Award, Evans Foundation, French National Cancer Institute

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 30-Mar-2015
Nature
How immune cells facilitate the spread of breast cancer
The body's immune system fights disease, infections and even cancer, acting like foot soldiers to protect against invaders and dissenters. But it turns out the immune system has traitors amongst their ranks. Dr. Karin de Visser and her team at the Netherlands Cancer Institute discovered that certain immune cells are persuaded by breast tumors to facilitate the spread of cancer cells. Their findings are published advanced online on March 30 in the journal Nature.
Dutch Cancer Society, Netherlands Organisation for Scientific Research, European Union

Contact: Nadine Boke
n.boke@nki.nl
31-205-126-284
Netherlands Cancer Institute

Public Release: 30-Mar-2015
Journal of Thoracic Oncology
Early stage NSCLC patients with low tumor metabolic activity have longer survival
Low pre-surgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer is associated with increased overall survival and a longer time before tumor recurrence. Patients with high labeled glucose uptake may benefit from additional therapy following surgery.

Contact: Murry Wynes
Murry.Wynes@iaslc.org
720-325-2945
International Association for the Study of Lung Cancer

Public Release: 30-Mar-2015
Oncotarget
Fasting and less-toxic cancer drug may work as well as chemotherapy
Fasting and kinase inhibitors work together to starve cancer cells.
Associazione Italiana per la Ricerca sul Cancro, Seventh Framework project PANCREAS, Compagnia di San Paolo; the Fondazione Umberto Veronesi, University of Genoa

Contact: Robert Perkins
perkinsr@usc.edu
213-740-9226
University of Southern California

Public Release: 30-Mar-2015
Journal of Clinical Investigation
Panel predicts whether rare leukemia will respond to treatment
Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers that predicted which tumor samples would likely respond to treatment.
Leukemia and Lymphoma Society, Sass Foundation, NIH/National Cancer Institute, US Department of Defense, Josie Robertson Investigator Program, Damon Runyon Clinical Investigator Award, The Evans Foundation, The French National Cancer Institute, and others

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 30-Mar-2015
Proceedings of the National Academy of Sciences
New drug stalls estrogen receptor-positive cancer cell growth and shrinks tumors
An experimental drug rapidly shrinks most tumors in a mouse model of human breast cancer, researchers report in the Proceedings of the National Academy of Sciences. When mice were treated with the experimental drug, BHPI, 'the tumors immediately stopped growing and began shrinking rapidly,' said University of Illinois biochemistry professor and senior author David Shapiro. 'In just 10 days, 48 out of the 52 tumors stopped growing, and most shrank 30 to 50 percent.'
NIH/National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Defense Breast Cancer Research Program

Contact: Diana Yates
diya@illinois.edu
217-333-5802
University of Illinois at Urbana-Champaign

Public Release: 30-Mar-2015
Journal of Clinical Oncology
Low vitamin D linked to worse prognosis in type of non-Hodgkin lymphoma
A new study found that people with lower vitamin D levels prior to treatment for follicular lymphoma succumb to the disease or face relapse earlier than patients with sufficient vitamin D levels in their blood.
NIH/National Cancer Institute

Contact: Lydia Fernandez
lydia_fernandez@urmc.rochester.edu
585-276-5788
University of Rochester Medical Center

Public Release: 30-Mar-2015
Nature
To stop cancer: Block its messages
Weizmann Institute scientists identify a potential drug molecule that stops cancer cells, but not healthy ones, from getting their 'mail.'

Contact: Yael Edelman
yael.edelman@weizmann.ac.il
Weizmann Institute of Science

Public Release: 30-Mar-2015
Experimental Biology 2015
New findings support the benefits of eating walnuts on overall health
Multiple new research abstracts suggest walnuts may have the potential to positively affect several important health factors. From their impact on colon cancer and certain aspects of cognitive aging, to their positive effect on both gut health and vascular health, the research findings presented at Experimental Biology 2015 detail our latest understanding of walnuts' inner workings. Running March 28 through April 1 in Boston, this annual meeting attracts an international audience of over 14,000 leading research scientists and exhibitors.
California Walnuts

Contact: Erin Farkaly
erin.farkaly@edelman.com
415-202-3503
Edelman Seattle

Public Release: 30-Mar-2015
Nature Nanotechnology
Princess Margaret scientists convert microbubbles to nanoparticles
Biomedical researchers led by Dr. Gang Zheng at Princess Margaret Cancer Centre have successfully converted microbubble technology already used in diagnostic imaging into nanoparticles that stay trapped in tumors to potentially deliver targeted, therapeutic payloads.

Contact: Jane Finlayson
jane.finlayson@uhn.ca
416-946-2846
University Health Network

Public Release: 30-Mar-2015
Journal of the National Cancer Institute
The CNIO identifies a new gene involved in hereditary neuroendocrine tumors
Mutations in the MDH2 gene, a key factor in cellular metabolism, are associated with the development of pheochromocytomas and paragangliomas, neuroendocrine tumors that affect the suprarenal and parathyroid glands, respectively. Up to 50 percent of patients inherit and/or transmit susceptibility to developing these tumors. The discovery will enable genetic diagnosis prior to the appearance of the disease.

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 30-Mar-2015
Nature Methods
High-tech method allows rapid imaging of functions in living brain
Researchers studying cancer and other invasive diseases rely on high-resolution imaging to see tumors and other activity deep within the body's tissues. Using a new high-speed, high-resolution imaging method, Lihong Wang, Ph.D., and his team at Washington University in St. Louis were able to see blood flow, blood oxygenation, oxygen metabolism and other functions inside a living mouse brain at faster rates than ever before.
National Institutes of Health, National Science Foundation

Contact: Julie Flory
julie.flory@wustl.edu
Washington University in St. Louis

Public Release: 27-Mar-2015
Nature Communications
MRI based on a sugar molecule can tell cancerous from noncancerous cells
Imaging tests like mammograms or CT scans can detect tumors, but figuring out whether a growth is or isn't cancer usually requires a biopsy to study cells directly. Now results of a Johns Hopkins study suggest that MRI could one day make biopsies more effective or even replace them altogether by noninvasively detecting telltale sugar molecules shed by the outer membranes of cancerous cells.
NIH/National Institute of Biomedical Imaging and Bioengineering, NIH/National Cancer Institute, Maryland Stem Cell Research Foundation, Pearl and Yueh-Heng Yang Foundation

Contact: Shawna Williams
shawna@jhmi.edu
410-955-8236
Johns Hopkins Medicine

Public Release: 27-Mar-2015
Nature Communications
The switch that might tame the most aggressive of breast cancers
Australian researchers have found that so-called 'triple-negative breast cancers' are two distinct diseases that likely originate from different cell types. They have also found a gene that drives the aggressive disease, and hope to find a way to 'switch it off'.
Cancer Institute of NSW, National Health and Medical Research Council of Australia, National Breast Cancer Foundation Australia, Cancer Council NSW, The Sydney Breast Cancer Foundation

Contact: Alison Heather
a.heather@garvan.org.au
61-292-958-128
Garvan Institute of Medical Research

Public Release: 27-Mar-2015
Nature Genetics
Integrative approaches key to understanding cancer, developing therapies, say Moffitt scientists
Moffitt Cancer Center researchers are using integrative approaches to study cancer by combining mathematical and computational modeling with experimental and clinical data. The use of integrative approaches enables scientists to study and model cancer progression in a manner that conventional experimental systems are unable to do.

Contact: Kim Polacek
Kim.Polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 27-Mar-2015
American Journal of Epidemiology
Study provides evidence against the fetal origins of cancer and cardiovascular disease
A study by researchers at Columbia's Mailman School of Public Health and in the Netherlands evaluated the relationship between nutritional conditions in early life and adult health, and found that famine exposure during the first pregnancy trimester was associated with increases in mortality from causes other than cancer or cardiovascular disease. This is the first study to quantify the possible long-term effects of nutrition deprivation at different stages of pregnancy and long-term mortality.
National Institutes of Health

Contact: Stephanie Berger
sb2247@columbia.edu
212-305-4372
Columbia University's Mailman School of Public Health

Public Release: 26-Mar-2015
EBioMedicine
Researcher overcomes radiation resistance in leukemia with an engineered precision medicine
A team of researchers led by Fatih M. Uckun, MD, PhD, of The Saban Research Institute of Children's Hospital Los Angeles and Professor at the University of Southern California Keck School of Medicine has determined that radiation resistance in leukemia can be overcome by using an engineered protein they recently designed and developed as a new precision medicine against leukemia.

Contact: Sacha Boucherie
s.boucherie@elsevier.com
31-204-853-564
Elsevier

Public Release: 26-Mar-2015
Nature Communications
Blocking cellular quality control mechanism gives cancer chemotherapy a boost
Scientists have found a new way to make chemotherapy more effective against breast cancer cells. They show that blocking a cellular quality control mechanism before administering chemotherapy makes breast cancer cells die faster than when they were exposed to chemotherapy alone. The work is a long way from being applied in people, but it could lead to new treatment strategies for patients in the future.
NIH/National Institute for General Medical Sciences, University of Rochester Wilmot Cancer Institute, Damon Runyon Cancer Research Foundation

Contact: Emily Boynton
emily_boynton@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center

Public Release: 26-Mar-2015
Clinical Gastroenterology and Hepatology
Female IBD patients: Stay up-to-date on your cervical cancer screening
Women with inflammatory bowel disease may be at increased risk of cervical dysplasia and cancer, according to a new study published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

Contact: Rachel Steigerwald
media@gastro.org
301-272-1603
American Gastroenterological Association

Public Release: 26-Mar-2015
CA: A Cancer Journal for Clinicians
Prostate cancer and treatment choices -- a decision shared by doctor and patient?
Doctors strive to make treatment decisions together with their patients -- but is the decision really shared? According to adjunct professor Kari Tikkinen, shared decision-making isn't easy, and clinicians need help. The international research group led by Tikkinen has studied the decision aids for treatment choice of localized prostate cancer. The study was published in the CA: A Cancer Journal for Clinicians, which has the highest impact factor of any journal.

Contact: Kari Tikkinen
kari.tikkinen@gmail.com
358-505-250-971
University of Helsinki

Public Release: 26-Mar-2015
Thyroid
Newly updated treatment guidelines for medullary thyroid carcinoma
A Task Force convened by the American Thyroid Association released updated guidelines for the diagnosis and treatment of medullary thyroid carcinoma. The current document is the first revision of the original guidelines published in 2009. The Task Force has presented their recommendations in the article 'Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma,' in Thyroid, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 26-Mar-2015
Cancer
Moffitt Cancer Center research aims to reduce health care disparities
The lesbian, gay, bisexual, transgender/transsexual, queer/questioning and intersex (LGBTQI) population has been largely understudied by the medical community. Researchers at Moffitt Cancer Center found that the LGBTQI community experience health disparities due to reduced access to health care and health insurance, coupled with being at an elevated risk for multiple types of cancer when compared to non-LGBTQI populations.

Contact: Kim Polacek
Kim.Polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 26-Mar-2015
Blood
Experts set strategic priorities for lymphoma research
A committee of lymphoma experts today unveiled a strategic roadmap identifying key priority areas in both infrastructure and research that will be critical for advancing treatments for people with lymphoma.

Contact: Amanda Szabo
aszabo@hematology.org
202-552-4914
American Society of Hematology

Public Release: 26-Mar-2015
2014 Western Surgical Association Annual Meeting
Journal of American College of Surgeons
Most women with early-stage breast cancer avoid extensive lymph node removal
A new study of women with early-stage breast cancer finds that surgeons no longer universally remove most of the lymph nodes in the underarm area when a biopsy of the nearby lymph nodes shows cancer -- a major change in breast cancer management.

Contact: Sally Garneski
pressinquiry@facs.org
312-202-5409
American College of Surgeons

Showing releases 151-175 out of 1291.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

  Search News Releases

     

Featured Multimedia

 

EurekAlert!